International consensus on radiotherapy in metastatic non-small cell lung cancer.
Fiche publication
Date publication
septembre 2022
Journal
Translational lung cancer research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr NOEL Georges
Tous les auteurs :
Zhu Z, Ni J, Cai X, Su S, Zhuang H, Yang Z, Chen M, Ma S, Xie C, Xu Y, Li J, Ge H, Liu A, Zhao L, Rao C, Xie C, Bi N, Hui Z, Zhu G, Yuan Z, Wang J, Zhao L, Zhou W, Rim CH, Navarro-Martin A, Vanneste BGL, Ruysscher D, Choi JI, Jassem J, Chang JY, Kepka L, Käsmann L, Milano MT, Van Houtte P, Suwinski R, Traverso A, Doi H, Suh YG, Noël G, Tomita N, Kowalchuk RO, Sio TT, Li B, Lu B, Fu X
Lien Pubmed
Résumé
Lung cancer is the leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) accounting for most cases. While radiotherapy has historically served as a palliative modality in metastatic NSCLC, considerable advances in its technology and the continuous development of cutting-edge therapeutic agents, such as targeted therapy and immune checkpoint inhibitors (ICIs), are increasing its role in the multi-disciplinary management of the disease.
Mots clés
Non-small cell lung cancer, brain metastasis, immune checkpoint inhibitor, oligo-metastasis, radiotherapy
Référence
Transl Lung Cancer Res. 2022 09;11(9):1763-1795